Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study.
Adaptation, Psychological
Adult
BRCA1 Protein
/ genetics
Female
France
/ epidemiology
Genetic Counseling
/ methods
Genetic Predisposition to Disease
/ psychology
Genetic Testing
/ methods
Germany
/ epidemiology
Hereditary Breast and Ovarian Cancer Syndrome
/ epidemiology
Humans
Psychology
Social Behavior
Spain
/ epidemiology
Stress, Psychological
/ diagnosis
hereditary breast and ovarian cancer
multigene
psychosocial problems
service delivery
targeted testing
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
24 09 2019
24 09 2019
Historique:
entrez:
26
9
2019
pubmed:
26
9
2019
medline:
21
10
2020
Statut:
epublish
Résumé
Advances in multigene panel testing for cancer susceptibility has increased the complexity of counselling, requiring particular attention to counselees' psychosocial needs. Changes in psychosocial problems before and after genetic testing were prospectively compared between genetic test results in women tested for breast or ovarian cancer genetic susceptibility in French, German and Spanish clinics. Among 752 counselees consecutively approached, 646 (86%) were assessed after the initial genetic consultation (T1), including 510 (68%) affected with breast cancer, of which 460 (61%) were assessed again after receiving the test result (T2), using questionnaires addressing genetic-specific psychosocial problems (Psychosocial Aspects of Hereditary Cancer (PAHC)-six scales). Sociodemographic and clinical data were also collected. Seventy-nine (17.2%), 19 (4.1%), 259 (56.3%), 44 (9.6%) and 59 (12.8%) women received a In women tested for breast or ovarian cancer genetic risk in European genetics clinics, psychosocial problems were mostly unaffected by genetic testing. Apart from women receiving a VUS result, those with another test result presented unchanged needs in counselling in particular about hereditary predisposition and familial/social issues.
Identifiants
pubmed: 31551380
pii: bmjopen-2019-029926
doi: 10.1136/bmjopen-2019-029926
pmc: PMC6773290
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e029926Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: PD reports grants from EU Horizon2020 programme during the conduct of the study.
Références
Br J Psychiatry. 1990 Jan;156:79-83
pubmed: 2297623
J Genet Couns. 2014 Apr;23(2):133-46
pubmed: 23996531
Patient Educ Couns. 2012 Feb;86(2):239-51
pubmed: 21684708
Bull Cancer. 2009 Sep;96(9):875-900
pubmed: 19751997
J Genet Couns. 2019 Apr;28(2):313-325
pubmed: 30636062
Cancer Treat Res. 2018;173:121-140
pubmed: 29349761
Ann Oncol. 2015 Oct;26(10):2057-65
pubmed: 26153499
Geburtshilfe Frauenheilkd. 2013 Jun;73(6):556-583
pubmed: 24771925
Psychooncology. 2014 Apr;23(4):420-7
pubmed: 24127257
Health Psychol. 2009 Jul;28(4):510-8
pubmed: 19594276
J Genet Couns. 2014 Aug;23(4):604-17
pubmed: 24599651
J Genet Couns. 2019 Oct;28(5):950-961
pubmed: 31199558
J Clin Oncol. 2013 Apr 1;31(10):1267-70
pubmed: 23460708
Gen Hosp Psychiatry. 2003 Jul-Aug;25(4):277-83
pubmed: 12850660
Psychooncology. 2014 Aug;23(8):862-9
pubmed: 24443031
Ann Behav Med. 2008 Oct;36(2):107-16
pubmed: 18787910
J Clin Oncol. 2011 Nov 10;29(32):4302-6
pubmed: 21990416
Fam Cancer. 2013 Sep;12(3):509-18
pubmed: 23264090
J Community Genet. 2011 Jun;2(2):53-69
pubmed: 22109790
Br J Cancer. 2013 Mar 19;108(5):1012-20
pubmed: 23462725
Br J Cancer. 2014 Jan 21;110(2):535-45
pubmed: 24346285
Fam Cancer. 2015 Dec;14(4):629-36
pubmed: 25968807
Psychooncology. 2012 Jan;21(1):29-42
pubmed: 21072753
Clin Transl Oncol. 2015 Dec;17(12):956-61
pubmed: 26669313
Int J Environ Res Public Health. 2018 Feb 12;15(2):
pubmed: 29439543
Psychooncology. 2009 Oct;18(10):1088-96
pubmed: 19214961
N Engl J Med. 2015 Jun 4;372(23):2243-57
pubmed: 26014596
J Community Genet. 2019 Oct;10(4):501-514
pubmed: 30919324
J Community Genet. 2019 Apr;10(2):189-196
pubmed: 30027524
J Med Genet. 2018 Jun;55(6):372-377
pubmed: 29661970
Eur J Hum Genet. 2016 Jun;24(6):794-802
pubmed: 26443265
J Genet Couns. 2017 Dec;26(6):1244-1253
pubmed: 28434142
Bull Cancer. 2018 Oct;105(10):907-917
pubmed: 30268633
J Genet Couns. 2017 Oct;26(5):1116-1129
pubmed: 28357778
Psychooncology. 2005 Dec;14(12):1060-74
pubmed: 15937976
Front Oncol. 2015 Sep 29;5:208
pubmed: 26484312
Health Psychol. 2009 Sep;28(5):569-578
pubmed: 19751083
J Genet Couns. 2018 Feb;27(1):289-300
pubmed: 28905158
Br J Cancer. 2001 Jan;84(2):179-85
pubmed: 11161373
Fam Cancer. 2016 Apr;15(2):341-50
pubmed: 26590592
Genet Med. 2016 Jan;18(1):25-33
pubmed: 25834950
Genet Med. 2011 Dec;13(12):998-1005
pubmed: 21811163
Fam Cancer. 2012 Jun;11(2):269-78
pubmed: 22350503
PLoS One. 2013 May 31;8(5):e65099
pubmed: 23741467
Science. 2014 Mar 28;343(6178):1466-70
pubmed: 24675953
Clin Genet. 2015 May;87(5):419-27
pubmed: 25130962
Fam Cancer. 2018 Jul;17(3):351-360
pubmed: 29124494
Psychooncology. 2013 Apr;22(4):902-10
pubmed: 22740372
Eur J Med Genet. 2019 May;62(5):300-307
pubmed: 30414532
Fam Cancer. 2015 Dec;14(4):495-504
pubmed: 25980896
Cancer. 2015 Feb 1;121(3):341-60
pubmed: 25234846
J Genet Couns. 2018 Feb;27(1):33-58
pubmed: 29022205
J Cancer Educ. 2019 Feb 9;:
pubmed: 30737640
PLoS Med. 2007 Oct 16;4(10):e297
pubmed: 17941715
Psychooncology. 2018 Jun;27(6):1530-1537
pubmed: 29498768
J Genet Couns. 2017 Jun;26(3):355-360
pubmed: 28236280